Clinical Trials
11 trialsNCT06787664 2026-04-13
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT02936102 2025-11-14
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT04246671 2025-03-03
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Bavarian Nordic
Phase 1 Completed
NCT03647423 2025-02-21
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT05355753 2024-12-17
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
C4 Therapeutics, Inc.
Phase 1 Terminated
NCT02383498 2024-05-20
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
NantCell, Inc.
Phase 2 Completed
NCT03595228 2023-04-14
BN Brachyury and Radiation in Chordoma
Bavarian Nordic
Phase 2 Completed
NCT01924689 2019-09-09
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
BioMed Valley Discoveries, Inc
Phase 1 Completed
NCT00150072 2017-02-23
Efficacy and Safety of Imatinib in Chordoma
Novartis
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed